About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Blogroll Update | Main | Still More Blogroll Additions »

May 11, 2009

Merck, Elsevier, and Fakery

Email This Entry

Posted by Derek

I've been meaning to write about the latest advance in salesmanship, pioneered by Merck and Elsevier. As most of you will have heard, the two collaborated to produce something called "The Australasian Journal of Bone and Joint Medicine". This appears to have looked like a real journal, complete with the Elsevier logo and a board of review editors, but it apparently featured nothing but articles (complimentary article, needless to say) about Merck products.

Update: It appears that Merck and Elsevier actually set up a whole publishing division, Excerpta Medica, to handle these things. More here and many more details here.

The news broke about a month ago in The Australian, and the story has been rolling downhill ever since, getting larger all the way. Now Elsevier has issued a public apology for their part in the whole affair, as well they should.

As Orac points out, there are a lot of "throwaway" journals out there, particularly in the medical field. These are sort of once-over-lightly review journals, condensing the literature down into short reads. And that's not all bad, although you wouldn't want a physician to be getting all his or her news that way. But this latest venture was designed to look like a real journal, and was, in fact, full of real articles which had been reprinted from other Elsevier journals. That's well over the line.

I'm not sure who to be more mad at here: Merck or Elsevier. This one really looks like a team effort. If Merck wants to assemble a bunch of previously peer-reviewed studies and put them out under some banner to show how wonderful their drugs were, well, that's fine by me. But that banner shouldn't be something that's deliberately designed to look like a peer-reviewed journal itself. And the collection should have a disclaimer on the cover that it's being paid for by Merck, and the first page of every article should have another box: "As originally reported in (journal citation) - brought to you as a service by Merck". I wouldn't have a problem with that at all.

But that (completely above-board) style seems to be just what the company wanted to avoid, and they got Elsevier, a large and (apparently spottily) respectable scientific publisher to say "Yes, indeed!". Merck's marketing people should be ashamed of themselves, but they should be ashamed for doing what they're paid to do too vigorously. Elsevier, on the other hand, shouldn't be doing this sort of thing at all.

Comments (18) + TrackBacks (0) | Category: Business and Markets | The Dark Side | The Scientific Literature


1. Alig on May 11, 2009 9:30 AM writes...

Money talks. I am sure Elsevier got paid a bunch to put out this journal. Is their apology going to include the donation of all that money to charity? If not, it'll mean nothing.

Permalink to Comment

2. DrZZ on May 11, 2009 9:36 AM writes...

It's not the only fake journal Elsevier put out. But all the money goes to science, right?

Permalink to Comment

3. Big Bob on May 11, 2009 9:41 AM writes...

Well it's not so much fakery, more an underhand marketing strategy, Elsevier really should have thought it through before risking tarnishing its reputation in this way.
I'm wondering how likely it would have been that these articles would have turned up in a search and if one of the offending articles were to come up in a search but not the original. For me it's like doing a search and having an article from New Scientist come up but not the original from Neurology that New Scientist is reporting on, which seems unlikely. In which case this really is nothing more than an expensive method of advertising.
I also notice that the journal was published between 2002 and's taken a while for this story to surface, is there any significance as to the timing? Conspiracy?
Oh dear it sounds as though I'm defending Merck, but since they didn't get back to me after a second round interview 15 years back I owe them nothing, not that I'm bitter about it!

Permalink to Comment

4. T on May 11, 2009 10:28 AM writes...

Ah, Elsevier - the black sheep of journal publishers.

Permalink to Comment

5. Muruga on May 11, 2009 10:54 AM writes...

It was unbelievable that two of the reputed companies, which are the icons of their own fields and said to follow strong corporate ethics, join together to indulge in an unacceptable practice. Hope, both Merck and Elsevier have realised the mistake. To err is human!

Permalink to Comment

6. Sili on May 11, 2009 12:29 PM writes...

Well. Given Reed-Elsevier's profitable weapons business, no├Âne's really too surprised by their ethics.

Permalink to Comment

7. hell to the chief on May 11, 2009 1:14 PM writes...

The quality of new Elsevier titles has been slowly decreasing over the years, but compared to Bentham, they are still paragons of virtue. Why would anyone need so many titles that contain essentially the same weak (and repetitive) so-called reviews, other than just to rip off libraries in academia and industry.
I see little need for any new scientific journals unless they address a genuinely new field. If your stuff is good enough, put it in a tried and tested title.

Permalink to Comment

8. Jose on May 11, 2009 3:25 PM writes...

Looking through the pdf of an issue on the Scientist website, I suspect very few MDs would take it seriously or not see through the charade. That said, using the reputable sounding citation to then cite the "articles" in other sources makes the whole thing exceedingly shady.

Permalink to Comment

9. bradpalm1 on May 11, 2009 3:49 PM writes...

Merck has fallen from the heights since the Medco merger fiasco years ago. It's amazing how they keep shooting themselves in the foot with these ill-conceived and compromising relationships. Their roster of medications is getting tired and their marketing arm seems in disarray. Of course, I don't know any company you can really point to anymore as a paragon of leadership.

Permalink to Comment

10. Mad on May 11, 2009 3:56 PM writes...

If all the articles were peer reviewed by other journals and just repackaged why are we supposed to be so upset? Are the slipping in other things not reviewed? Are there changes to the text vs the originals?

Permalink to Comment

11. Anonymous on May 11, 2009 6:34 PM writes...

Not surprised by this at all. Merck is not an ethical company any more.

Permalink to Comment

12. Bruce Hamilton on May 11, 2009 7:47 PM writes...

I wonder if this "division" is actually just a small add-on group to their Excerpta Medica database ( EMBase ), which used to be the medical equivalent of CAS?.

If so, they're giving the whole respected division a very bad name.

Permalink to Comment

13. p.e. on May 11, 2009 8:40 PM writes...

Would this be a bad time to argue in favor of open-access not-for-profit journals?

Permalink to Comment

14. bcpmoon on May 12, 2009 12:32 AM writes...

Sometimes I think, the marketing people should be trained in HAZOP-Studies: What can go wrong, what to do then and how to minimize casualties. They seem like children to me, not comprehending the real world when it inevitable calls to dinner.

Permalink to Comment

15. AR on May 12, 2009 7:39 AM writes...

Worked at a large pharma that was fined a whopping 800 million for ethics violations. Over the next 5 years all company employees were subjected to endless computer ethics modules that sucked up a lot of time. Rumor was that the senior execs just had to log in and out and not actually complete the modules.

Permalink to Comment

16. TJ on May 13, 2009 11:30 AM writes...

"our Australia office" and "....and we regret that it took place" does not exactly sound like a humble apology from a company taking responsibility for their actions. Another sad day for scientific publishing.

Permalink to Comment

17. Kate Zeiss on June 26, 2009 6:53 AM writes...

Thought you might find this Merck Frosst PR interesting. It's from 2007, advertising one-click, all-in-one-place research info for practitioners - claim 400,000 subscribers. Names Excerpta Medica and Elsevior as primary sources

Permalink to Comment

18. Kate Zeiss on June 26, 2009 6:55 AM writes...

Thought you might find this Merck Frosst PR interesting. It's from 2007, advertising one-click, all-in-one-place research info for practitioners - claim 400,000 subscribers. Names Excerpta Medica and Elsevior as primary sources

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry